Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K011963
    Manufacturer
    Date Cleared
    2001-11-20

    (151 days)

    Product Code
    Regulation Number
    862.1345
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Glucose Hexokinase II in vitro diagnostic procedure is intended to measure glucose in human serum, plasma and urine on the Bayer ADVIA® 1650 System. Such measurement is used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia and insulin overdose.

    Device Description

    The Glucose Hexokinase II in vitro diagnostic procedure is intended to measure glucose in human serum, plasma and urine on the Bayer ADVIA® 1650 System. The assay buffer is in dual aliquots, allowing for blanking and subtraction of potential interference effects.

    AI/ML Overview

    Acceptance Criteria and Device Performance for Glucose Hexokinase II method for Bayer ADVIA® 1650 System (K011963)

    This submission (K011963) is a 510(k) for a new version of a Glucose Hexokinase assay, called Glucose Hexokinase II, for the Bayer ADVIA® 1650 System. The submission claims substantial equivalence to the predicate device, also a Glucose Hexokinase assay (K991576). The "acceptance criteria" can be inferred from the reported performance of the predicate device, with the new device demonstrating comparable or improved performance.

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria are not explicitly stated as numerical thresholds in this 510(k) summary. Instead, the sponsor demonstrates that the new device's performance characteristics (Imprecision, Correlation, Interfering Substances, Analytical Range) are comparable to, or improved relative to, those of the predicate device.

    Performance CharacteristicAcceptance Criteria (Predicate Device Performance)Reported Device Performance (Glucose Hexokinase II)
    Imprecision (Total CV%)
    Serum (low)2.4% at 77 mg/dL2.2% at 75 mg/dL
    Serum (high)3.3% at 279 mg/dL2.2% at 279 mg/dL
    Urine (low)3.5% at 42 mg/dL4.1% at 46 mg/dL
    Urine (high)3.6% at 285 mg/dL3.6% at 267 mg/dL
    Correlation: Regression Equation (Y=new, X=predicate)Close to Y=1.00x + 0.00
    SerumY=1.02x-1.84Y=1.02x-1.84
    UrineY=0.97x-7.44Y=0.97x-7.44
    Plasma vs Serum*Y=1.001x+0.088Y=1.001x+0.088
    Correlation: R-valueHigh (e.g., >0.99)
    Serum0.9980.998
    Urine0.9990.999
    Plasma vs Serum*0.99970.9997
    Correlation: Syx (mg/dL)Low (e.g.,
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1